Compare Open Text Corporation (OTEX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs Twist Bioscience Corp — how do they compare? Open Text Corporation trades at $22.6 (market cap $5.64B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Open Text Corporation pays a 4.8% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| OTEX | TWST | |
|---|---|---|
Market Cap | $5.64B | $8.42B |
Sector | Technology | Health |
52-Week High | $39.69 | $153.10 |
52-Week Low | $20.01 | $24.16 |
Enterprise Value | $10.66B | $8.35B |
Dividend Yield | 4.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Open Text Corp (OTEX) trades at $23.36, down 2.46% on the day, with a bearish technical signal but attractive valuation multiples (P/E 9.05, P/S 1.11). Recent earnings beats (Q4 2025, Q1 2026, Q2 2026) and a 4.7% dividend yield highlight fundamental strength. The company announced a $105 million investment in European AI and cloud expansion (PRNewsWire, 2026-06-12), signaling growth initiatives amid mixed institutional positioning.
Outlook: Undervalued with strong cash flow and earnings momentum, but near-term technical pressure and high debt ($6.34B) pose risks. Analyst consensus target of $29.33 suggests 25% upside, supported by cloud revenue growth. Key risks include execution on AI investments and competitive software market dynamics.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
